ESICM TRIALS GROUP
ESICM Trials Group
ESICM aims to foster collaborative research among its members and to promote European Intensive Care Research. Since 2013, 15 Trial Group studies have enrolled 41 441 patients in total. All studies, observational or interventional, were international multicentric. The Trial Group contributed to the advancement of knowledge of research in intensive care.
Learn more about legislations related to Clinical Trials: here
Learn more about our ongoing endorsed projects: here
Learn more about our completed endorsed projects: here
learn more about our completed supported projects: here
PARTICIPATE IN OUR OPEN TRIALS
The ESICM Trials Group has major trials which are either currently or soon to open for interested centres. Learn more about SYNAPSE-ICU, TRAIN, VITDALIZE, PrevAKI, DecubICUs and WEAN SAFE and register your interest in getting your ICU involved in these important clinical research initiatives in intensive care medicine! See all of the dedicated webpages for more information.
ESICM has supported several other long-term studies in recent years.
GenOSept: Genetics of Sepsis in Europe
It is hypothesised that the fatal outcome following treatment for severe sepsis is, in part, genetically determined. This hypothesis is based on preliminary data developed by several groups from studies of small, relatively homogeneous populations. GenOSept will test this hypothesis through three phases:
- A genetic epidemiologic study of genetic predisposition to sepsis-related mortality and morbidity in European intensive care units;
- This unique European dataset on the effect of genetic variation on sepsis outcomes will help to explain variation in response to new treatments for sepsis, will deliver data on gender related mortality and morbidity;
- Harmonisation of standards for European high throughput genotyping and quality control by co-ordinating three major European genotyping centres (Wellcome Trust Centre for Human Genetics – Oxford, Cochin Institute – Paris, Helmholtz Zentrum Munchen – Munich).
This project was supported by ESICM.